Literature DB >> 10434057

The reaction of deoxy-sickle cell hemoglobin with hydroxyurea.

D B Kim-Shapiro1, S B King, H Shields, C P Kolibash, W L Gravatt, S K Ballas.   

Abstract

In addition to its capacity to increase fetal hemoglobin levels, other mechanisms are implicated in hydroxyurea's ability to provide beneficial effects to patients with sickle cell disease. We hypothesize that the reaction of hemoglobin with hydroxyurea may play a role. It is shown that hydroxyurea reacts with deoxy-sickle cell hemoglobin (Hb) to form methemoglobin (metHb) and nitrosyl hemoglobin (HbNO). The products of the reaction as well as the kinetics are followed by absorption spectroscopy and electron paramagnetic resonance (EPR) spectroscopy. Analysis of the kinetics shows that the reaction can be approximated by a pseudo-first order rate constant of 3.7x10(-4) (1/(s.M)) for the disappearance of deoxy-sickle cell hemoglobin. Further analysis shows that HbNO is formed at an observed average rate of 5.25x10(-5) (1/s), three to four times slower than the rate of formation of metHb. EPR spectroscopy is used to show that the formation of HbNO involves the specific transfer of NO from the NHOH group of hydroxyurea. The potential importance of this reaction is discussed in the context of metHb and HbNO being able to increase the delay time for sickle cell hemoglobin polymerization and HbNO's vasodilating capabilities through conversion to S-nitrosohemoglobin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434057     DOI: 10.1016/s0304-4165(99)00071-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

2.  Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.

Authors:  Vladan P Cokic; Silvana A Andric; Stanko S Stojilkovic; Constance T Noguchi; Alan N Schechter
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

3.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.

Authors:  Vladan P Cokic; Reginald D Smith; Bojana B Beleslin-Cokic; Joyce M Njoroge; Jeffery L Miller; Mark T Gladwin; Alan N Schechter
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

4.  Interactions of nitrosylhemoglobin and carboxyhemoglobin with erythrocyte.

Authors:  Katherine J Chou; Joanna Dodd; James C Liao
Journal:  Nitric Oxide       Date:  2007-11-07       Impact factor: 4.427

5.  Antisickling Drugs Targeting βCys93 Reduce Iron Oxidation and Oxidative Changes in Sickle Cell Hemoglobin.

Authors:  Tigist Kassa; Francine Wood; Michael Brad Strader; Abdu I Alayash
Journal:  Front Physiol       Date:  2019-07-24       Impact factor: 4.566

6.  Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia".

Authors:  Eduard Johannes van Beers; Gregory James Kato
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.